NCT00438971View on ClinicalTrials.gov

The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Panic Disorder
Interventions
DRUG

Duloxetine

Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.

Trial Locations (1)

02114

The Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00438971 - The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder | Biotech Hunter | Biotech Hunter